Santiago Ponce

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 20, 2026

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Journal: Cancers

Published: September 21, 2025

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 25, 2025

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

Journal: JCO precision oncology

Published: June 04, 2025

Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors.

Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors.

Journal: Investigational new drugs

Published: May 29, 2025

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.

Journal: JTO clinical and research reports

Published: April 28, 2025

Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.

Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.

Journal: Radiology

Published: November 26, 2024

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 19, 2024

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: August 22, 2023

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.

Journal: Journal for immunotherapy of cancer

Published: August 04, 2023

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: June 28, 2023

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 13, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026